Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.

Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics. Asian Pac J Cancer Prev. 2019 Jun 01;20(6):1691-1699 Authors: Gilani JA, Ashfaq MA, Mansoor AE, Abdul Jabbar A, Siddiqui T, Khan M Abstract Primary Myelofibrosis is a BCR-ABL negative myeloproliferative neoplasm with a variety of hematological<br />presentations, including thrombosis, bleeding diathesis and marrow fibrosis. It is estimated to have an incidence of<br />1.5 per 100,000 people each year. Although JAK2 or MPL mutations are seen in PMF, several other mutations have<br />recently been documented, including mutations in CALR, epigenetic regulators like TET, ASXL1, and 13q deletions.<br />The identification of these mutations has improved the ability to develop novel treatment options. These include JAK<br />inhibitors like ruxolitinib, heat shock protein-90 inhibitors like ganetespib, histone deacetylase inhibitors including<br />panobinostat, pracinostat, vorinostat and givinostat, hypomethylating agents like decitabine, hedgehog inhibitors like<br />glasdegib, PI3K, AKT and mTOR inhibitors like everolimus as well as telomerase inhibitors like imtelstat. Research<br />on novel therapeutic options is being actively pursued in order to expand treatment options for primary myelofibrosis<br />however currently, there is no curative therapy other than allogenic hematopoietic ste...
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research